Could Diageo plc & Fevertree Drinks PLC Be The Tonic Your Portfolio Needs?

Tonic maker Fevertree Drinks PLC (LON: FEVR) offers plenty of fizz but Harvey Jones fears that drinks giant Diageo plc (LON: DGE) lacks spirit.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

If ever a stock pairing was made for each other, then it should be these two. Gin & tonic is the hipster tipple of choice these days, as the once-fusty-but-always-fabulous drink storms back into fashion. So why not combine a dash of global drinks giant Diageo (LSE: DGE) with a splash of tonic maker Fevertree Drinks (PLC: FVER)?

Drink problem

Premium drinks business Diageo serves up a lot more than Tanqueray gin, its other giant global brands include Johnnie Walker, Smirnoff, Captain Morgan, Baileys and Guinness. Yet recent share price performance has been weak, with the stock down 5% over the last three years. I sold my stake around in 2013 after deciding that the glory growth years under departing chief executive Paul Walsh were over. Successor Ivan Menezes has still to convince me otherwise.

Revenues slipped slightly in the six months to 31 December, from ÂŁ8.72bn, partly due to adverse currency movements and the offloading of ÂŁ400m of non-core assets. Pre-tax profit did edge up from ÂŁ1.64bn to ÂŁ1.78bn year-on-year and Menezes hailed growing volumes, improved key brand performance and strong cash flows. Yet I still can’t recapture my taste for this stock.

Growth potential is tight as Chinese authorities curb gift-giving and emerging market consumers no longer feel so flush. The US has also been sluggish, which makes me wonder whether Diageo is on the wrong end of a trend. Western consumers increasingly seek quality over quantity as the foodie fad extends to the drinks trade: artisan gins now trump the old duty-free favourites. To be fair, Menezes has countered this with his Drink Better premium brands strategy, but Diageo faces stiff competition.

Tree of life

Rather than reacting to changing drinking trends, Fevertree Drinks is driving them. Its Indian Tonic Waters claim to only contain “the highest quality natural ingredients”, shunning the artificial sweeteners, preservatives or flavourings found in mainstream brands. And the foodies (or drinkies) love it. Fevertree has been awarded Cool Brands Status for four consecutive years and aims to launch a new product each year. Just glancing at its website made me feel thirsty.

Fevertree is more than just a cool brand, with its recent trading update anticipating a 77% rise in second half sales and 71% growth in revenues to ÂŁ59.2m. UK sales (up 84%) are leading the way but I’m glad to see it making inroads into the larger US and European markets, with sales up around 65% in both. Diageo, by comparison, has been forced to dispatch its former CFO to turn things around in the US. It expects sales to rise 8.5% but that looks pallid compared to Fevertree’s flush of growth.

Diageo’s share price has been flat over the last year while Fevertree is up a sparkling 195%, making it a pure momentum play. It has repeatedly beaten its own expectations but its sky-high valuation of 203 times earnings means it must continue to do so.

After writing this I fancy a heady mix of Tanqueray and Fevertree myself, but as it’s still morning I’ll keep a clear head and raise my glass to Fevertree.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK has recommended Diageo. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »